This Core will provide high-fidelity measures of cardiac physiology for the various mouse lines described in the 3 Projects and provide models of cardiac injury for all Projects to study. Specifically, this Core Unit will be responsible for providing 1) mouse models of cardiac hypertrophy and ischemic injury where both models can lead to heart failure (HF), 2) complete and comprehensive cardiovascular physiology measurements (phenotyping) of all mouse models detailed through the PPG application, and 3) cardiac viral-mediated gene delivery. Surgical mouse models include coronary artery occlusion models for ischemia/reperfusion (l/R) injury or complete coronary artery ligation producing a myocardial infarction (Ml). Also, transverse aortic constriction (TAC) for models of hypertrophy and HF will be handled in this Core. The Core will also help investigators with surgical implantation of AzIet mini-osmotic pumps for chronic drug delivery. Further, cardiac viral-mediated gene delivery can be done either though IV injection or more invasively directly to the heart as seen in this application. Comprehensive mouse cardiovascular physiological phenotyping includes in-depth assessment of murine in vivo cardiac function via echocardiography and hemodynamic measurements via Millar catheterization. Further, this Core will assess conscious blood pressure and electric cardiogram (ECG) using telemetry. This Core will be utilized by all Projects and will continue to be instrumental in providing reproducible and high-quality mouse models of cardiac injury and physiological cardiovascular phenotyping.
Mouse models of cardiac injury have been key tools to delineate novel mechanisms of heart failure development and to also test unique therapeutic strategies for repair of the failing heart. This Core is instrumental to the success of all Projects within this PPG and will continue to provide significant support in animal model and cardiovascular phenotyping.
|Tahrir, Farzaneh G; Shanmughapriya, Santhanam; Ahooyi, Taha Mohseni et al. (2018) Dysregulation of mitochondrial bioenergetics and quality control by HIV-1 Tat in cardiomyocytes. J Cell Physiol 233:748-758|
|Myers, Valerie D; McClung, Joseph M; Wang, JuFang et al. (2018) The Multifunctional Protein BAG3: A Novel Therapeutic Target in Cardiovascular Disease. JACC Basic Transl Sci 3:122-131|
|Myers, Valerie D; Tomar, Dhanendra; Madesh, Muniswamy et al. (2018) Haplo-insufficiency of Bcl2-associated athanogene 3 in mice results in progressive left ventricular dysfunction, ?-adrenergic insensitivity, and increased apoptosis. J Cell Physiol 233:6319-6326|
|Borghetti, Giulia; von Lewinski, Dirk; Eaton, Deborah M et al. (2018) Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol 9:1514|
|Grisanti, Laurel A; Schumacher, Sarah M; Tilley, Douglas G et al. (2018) Designer Approaches for G Protein-Coupled Receptor Modulation for Cardiovascular Disease. JACC Basic Transl Sci 3:550-562|
|de Lucia, Claudio; Eguchi, Akito; Koch, Walter J (2018) New Insights in Cardiac ?-Adrenergic Signaling During Heart Failure and Aging. Front Pharmacol 9:904|
|Grisanti, Laurel A; Thomas, Toby P; Carter, Rhonda L et al. (2018) Pepducin-mediated cardioprotection via ?-arrestin-biased ?2-adrenergic receptor-specific signaling. Theranostics 8:4664-4678|
|Cannavo, Alessandro; Koch, Walter J (2018) GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease. Cell Signal 41:33-40|
|Yeh, Szu-Tsen; Zambrano, Cristina M; Koch, Walter J et al. (2018) PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro. J Biol Chem 293:8056-8064|
|de Lucia, Claudio; Gambino, Giuseppina; Petraglia, Laura et al. (2018) Long-Term Caloric Restriction Improves Cardiac Function, Remodeling, Adrenergic Responsiveness, and Sympathetic Innervation in a Model of Postischemic Heart Failure. Circ Heart Fail 11:e004153|
Showing the most recent 10 out of 163 publications